AMSTERDAM, May 13, 2026 /3BL/ – SCS Global Services (SCS), a global leader in third-party environmental and sustainability assurance, today announced expanded services under the European Union Emissions Trading System (EU ETS), as SCS Global Services Europe B.V. (SCS Europe) progresses through accreditation for the following activity groups:

  • Activity Group 4 – Production of (non)‑ferrous metals 
  • Activity Group 8 – Chemical industry activities 

SCS Europe is uniquely positioned to serve ETS verification expectations through its combined experience across EU regulatory programs, including CBAM, EUDR, and RED III, and its ability to deliver independent pre-verification assessments aligned with accredited verification requirements.

“As EU ETS requirements become more complex and scrutiny around emissions data continues to increase, organizations are recognizing the need for independent, verification-aligned assessments earlier in the process,” said Vanessa Ellis, Director of Program Development at SCS Europe. “Our approach provides that early visibility, giving organizations a clear view of how their systems and data will hold up under third-party verification while maintaining the independence required for accredited assurance.”

While the accreditation process is ongoing, SCS Europe is actively providing operators through a suite of services designed to highlight readiness and identify potential compliance risk ahead of formal verification.

These services include a free EU ETS Readiness Tool, which enables operators to carry out a confidential self‑assessment to understand their current level of readiness and highlight potential areas of misalignment with EU ETS monitoring, reporting, and control systems.

SCS Europe also provides preverification services, conducted with the same technical rigor as accredited verification without issuing a formal verification opinion. These independent assessments identify risks related to emissions data accuracy, monitoring plans, data flows, and compliance with the EU ETS Monitoring and Reporting Regulation (MRR), providing visibility into readiness gaps and potential compliance risks.

In addition, informational sessions are offered as part of pre‑verification engagements, covering requirements, compliance timelines, the verification process, and common findings, so operators and responsible staff can better understand verification expectations ahead of their pre-verification.

Operators interested in assessing their readiness ahead of upcoming reporting cycles are encouraged to begin with the free EU ETS Readiness Tool or connect with an SCS specialist.

About SCS Global Services Europe

SCS Global Services Europe is an affiliated company of SCS Global Services, a pioneer and leader in the field of sustainability standards and third-party certification, working across the economy in the natural resources, built environment, food and agriculture, consumer products, and climate sectors for over 40 years. Partnering with European companies, government agencies, NGOs, and stakeholders, we are striving to advance sustainable development goals through independent assessment, the application of sound science, and innovative solutions. Through these services, we are enabling decision-makers and purchasers to make informed decisions, giving innovators a competitive edge, and helping to drive the development of leadership standards to create a framework for continuous improvement. SCS is a California-chartered Benefit Corporation, reflecting its commitment to socially and environmentally responsible business practices.  SCS is also a Participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business.

Media Contact

Rachel Barnhart
Director of Corporate Communications and Public Relations
rbarnhart@scsglobalservices.com

AMSTERDAM, May 13, 2026 /3BL/ – SCS Global Services (SCS), a global leader in third-party environmental and sustainability assurance, today announced expanded services under the European Union Emissions Trading System (EU ETS), as SCS Global Services Europe B.V. (SCS Europe) progresses through accreditation for the following activity groups:

  • Activity Group 4 – Production of (non)‑ferrous metals 
  • Activity Group 8 – Chemical industry activities 

SCS Europe is uniquely positioned to serve ETS verification expectations through its combined experience across EU regulatory programs, including CBAM, EUDR, and RED III, and its ability to deliver independent pre-verification assessments aligned with accredited verification requirements.

“As EU ETS requirements become more complex and scrutiny around emissions data continues to increase, organizations are recognizing the need for independent, verification-aligned assessments earlier in the process,” said Vanessa Ellis, Director of Program Development at SCS Europe. “Our approach provides that early visibility, giving organizations a clear view of how their systems and data will hold up under third-party verification while maintaining the independence required for accredited assurance.”

While the accreditation process is ongoing, SCS Europe is actively providing operators through a suite of services designed to highlight readiness and identify potential compliance risk ahead of formal verification.

These services include a free EU ETS Readiness Tool, which enables operators to carry out a confidential self‑assessment to understand their current level of readiness and highlight potential areas of misalignment with EU ETS monitoring, reporting, and control systems.

SCS Europe also provides preverification services, conducted with the same technical rigor as accredited verification without issuing a formal verification opinion. These independent assessments identify risks related to emissions data accuracy, monitoring plans, data flows, and compliance with the EU ETS Monitoring and Reporting Regulation (MRR), providing visibility into readiness gaps and potential compliance risks.

In addition, informational sessions are offered as part of pre‑verification engagements, covering requirements, compliance timelines, the verification process, and common findings, so operators and responsible staff can better understand verification expectations ahead of their pre-verification.

Operators interested in assessing their readiness ahead of upcoming reporting cycles are encouraged to begin with the free EU ETS Readiness Tool or connect with an SCS specialist.

About SCS Global Services Europe

SCS Global Services Europe is an affiliated company of SCS Global Services, a pioneer and leader in the field of sustainability standards and third-party certification, working across the economy in the natural resources, built environment, food and agriculture, consumer products, and climate sectors for over 40 years. Partnering with European companies, government agencies, NGOs, and stakeholders, we are striving to advance sustainable development goals through independent assessment, the application of sound science, and innovative solutions. Through these services, we are enabling decision-makers and purchasers to make informed decisions, giving innovators a competitive edge, and helping to drive the development of leadership standards to create a framework for continuous improvement. SCS is a California-chartered Benefit Corporation, reflecting its commitment to socially and environmentally responsible business practices.  SCS is also a Participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business.

Media Contact

Rachel Barnhart
Director of Corporate Communications and Public Relations
rbarnhart@scsglobalservices.com

SHANGHAI, May 12, 2026 /PRNewswire/ — WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that, in recognition of its continued efforts and exceptional performance in advancing sustainability, the Company has been included in the 2026 Dow Jones Best‑in‑Class World Index (DJ BIC World) and the Dow Jones Best‑in‑Class Emerging Markets Index (DJ BIC Emerging Markets).

Through S&P Global’s Corporate Sustainability Assessment (CSA), the DJ BIC World Index and the DJ BIC Emerging Markets Index identify sustainability leaders that rank in the top 10% based on their long-term economic, environmental and social performance, selecting from the largest 2,500 global companies in the S&P Global Broad Market Index (BMI) and from the largest 800 companies across 20 emerging markets, respectively.

Based on the 2025 CSA, WuXi Biologics ranked among the top 1% globally within its industry and was included in the S&P Global Sustainability Yearbook for the fourth consecutive year.

Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented, “We are honored to be included in both the DJ BIC World Index and the DJ BIC Emerging Markets Index. This recognition reflects our long‑term commitment to sustainability and the continuous enhancement of our overall performance across environmental, social and governance dimensions. As a global leader in Green CRDMO, WuXi Biologics continues to integrate ESG into its business strategy and operations, delivering innovative end‑to‑end solutions to our global partners. Going forward, we will keep pushing industry boundaries, collaborating with all our stakeholders to promote responsible and sustainable practices throughout the entire value chain.”

Over the years, WuXi Biologics’ consistent efforts to promote sustainable development have received notable recognition from leading global ESG rating agencies, including MSCI AAA Ratings; EcoVadis Platinum Medals; “A List” status from CDP for Climate Change, Water Security, and Supplier Engagement Assessment; the highest negligible-risk rating by Morningstar Sustainalytics, and designation as a Sustainalytics industry and regional ESG Leader; inclusion in the FTSE4Good Index Series; a “Prime” designation from ISS ESG Rating; and inclusion in the Hang Seng Corporate Sustainability Benchmark Index.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 13,000 employees in China, the United States, Ireland, Germany, and Singapore — including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence — WuXi Biologics leverages its technologies and expertise to deliver efficient, cost-effective, and scalable biologics solutions tailored to meet clients’ needs. By embedding digital capability and infrastructure across the full biopharmaceutical value chain, the company turns data, computation, and prediction into transparent client experience, faster development, intelligent operations, and more efficient manufacturing. As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while demonstrating exemplary Environmental, Social and Governance (ESG) practices. Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com

Contacts

Media
PR@wuxibiologics.com 

ESG
esg@wuxibiologics.com 

Cision View original content:https://www.prnewswire.com/news-releases/wuxi-biologics-included-in-2026-dow-jones-bestinclass-world-index-and-emerging-markets-index-302770333.html

SOURCE WuXi Biologics

SHANGHAI, May 12, 2026 /PRNewswire/ — WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that, in recognition of its continued efforts and exceptional performance in advancing sustainability, the Company has been included in the 2026 Dow Jones Best‑in‑Class World Index (DJ BIC World) and the Dow Jones Best‑in‑Class Emerging Markets Index (DJ BIC Emerging Markets).

Through S&P Global’s Corporate Sustainability Assessment (CSA), the DJ BIC World Index and the DJ BIC Emerging Markets Index identify sustainability leaders that rank in the top 10% based on their long-term economic, environmental and social performance, selecting from the largest 2,500 global companies in the S&P Global Broad Market Index (BMI) and from the largest 800 companies across 20 emerging markets, respectively.

Based on the 2025 CSA, WuXi Biologics ranked among the top 1% globally within its industry and was included in the S&P Global Sustainability Yearbook for the fourth consecutive year.

Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented, “We are honored to be included in both the DJ BIC World Index and the DJ BIC Emerging Markets Index. This recognition reflects our long‑term commitment to sustainability and the continuous enhancement of our overall performance across environmental, social and governance dimensions. As a global leader in Green CRDMO, WuXi Biologics continues to integrate ESG into its business strategy and operations, delivering innovative end‑to‑end solutions to our global partners. Going forward, we will keep pushing industry boundaries, collaborating with all our stakeholders to promote responsible and sustainable practices throughout the entire value chain.”

Over the years, WuXi Biologics’ consistent efforts to promote sustainable development have received notable recognition from leading global ESG rating agencies, including MSCI AAA Ratings; EcoVadis Platinum Medals; “A List” status from CDP for Climate Change, Water Security, and Supplier Engagement Assessment; the highest negligible-risk rating by Morningstar Sustainalytics, and designation as a Sustainalytics industry and regional ESG Leader; inclusion in the FTSE4Good Index Series; a “Prime” designation from ISS ESG Rating; and inclusion in the Hang Seng Corporate Sustainability Benchmark Index.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 13,000 employees in China, the United States, Ireland, Germany, and Singapore — including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence — WuXi Biologics leverages its technologies and expertise to deliver efficient, cost-effective, and scalable biologics solutions tailored to meet clients’ needs. By embedding digital capability and infrastructure across the full biopharmaceutical value chain, the company turns data, computation, and prediction into transparent client experience, faster development, intelligent operations, and more efficient manufacturing. As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while demonstrating exemplary Environmental, Social and Governance (ESG) practices. Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com

Contacts

Media
PR@wuxibiologics.com 

ESG
esg@wuxibiologics.com 

Cision View original content:https://www.prnewswire.com/news-releases/wuxi-biologics-included-in-2026-dow-jones-bestinclass-world-index-and-emerging-markets-index-302770333.html

SOURCE WuXi Biologics

SHANGHAI, May 12, 2026 /PRNewswire/ — WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that, in recognition of its continued efforts and exceptional performance in advancing sustainability, the Company has been included in the 2026 Dow Jones Best‑in‑Class World Index (DJ BIC World) and the Dow Jones Best‑in‑Class Emerging Markets Index (DJ BIC Emerging Markets).

Through S&P Global’s Corporate Sustainability Assessment (CSA), the DJ BIC World Index and the DJ BIC Emerging Markets Index identify sustainability leaders that rank in the top 10% based on their long-term economic, environmental and social performance, selecting from the largest 2,500 global companies in the S&P Global Broad Market Index (BMI) and from the largest 800 companies across 20 emerging markets, respectively.

Based on the 2025 CSA, WuXi Biologics ranked among the top 1% globally within its industry and was included in the S&P Global Sustainability Yearbook for the fourth consecutive year.

Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented, “We are honored to be included in both the DJ BIC World Index and the DJ BIC Emerging Markets Index. This recognition reflects our long‑term commitment to sustainability and the continuous enhancement of our overall performance across environmental, social and governance dimensions. As a global leader in Green CRDMO, WuXi Biologics continues to integrate ESG into its business strategy and operations, delivering innovative end‑to‑end solutions to our global partners. Going forward, we will keep pushing industry boundaries, collaborating with all our stakeholders to promote responsible and sustainable practices throughout the entire value chain.”

Over the years, WuXi Biologics’ consistent efforts to promote sustainable development have received notable recognition from leading global ESG rating agencies, including MSCI AAA Ratings; EcoVadis Platinum Medals; “A List” status from CDP for Climate Change, Water Security, and Supplier Engagement Assessment; the highest negligible-risk rating by Morningstar Sustainalytics, and designation as a Sustainalytics industry and regional ESG Leader; inclusion in the FTSE4Good Index Series; a “Prime” designation from ISS ESG Rating; and inclusion in the Hang Seng Corporate Sustainability Benchmark Index.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 13,000 employees in China, the United States, Ireland, Germany, and Singapore — including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence — WuXi Biologics leverages its technologies and expertise to deliver efficient, cost-effective, and scalable biologics solutions tailored to meet clients’ needs. By embedding digital capability and infrastructure across the full biopharmaceutical value chain, the company turns data, computation, and prediction into transparent client experience, faster development, intelligent operations, and more efficient manufacturing. As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while demonstrating exemplary Environmental, Social and Governance (ESG) practices. Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com

Contacts

Media
PR@wuxibiologics.com 

ESG
esg@wuxibiologics.com 

Cision View original content:https://www.prnewswire.com/news-releases/wuxi-biologics-included-in-2026-dow-jones-bestinclass-world-index-and-emerging-markets-index-302770333.html

SOURCE WuXi Biologics

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.